Format

Send to

Choose Destination
Clin Lung Cancer. 2019 Mar;20(2):e137-e141. doi: 10.1016/j.cllc.2018.11.003. Epub 2018 Nov 20.

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Author information

1
Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
2
Department of Surgery, University of California, San Francisco, San Francisco, CA.
3
Department of Pathology, University of California, San Francisco, San Francisco, CA.
4
Department of Radiology, University of California, San Francisco, San Francisco, CA.
5
Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Electronic address: Collin.blakely@ucsf.edu.

KEYWORDS:

Non-small cell lung cancer; Perioperative; Stage III; Targeted therapy; Tyrosine kinase inhibitor

PMID:
30553716
DOI:
10.1016/j.cllc.2018.11.003
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center